Literature DB >> 16972715

Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.

Heinz Schmidli1, Frank Bretz, Amy Racine, Willi Maurer.   

Abstract

Adaptive seamless phase II/III designs combine a phase II and a phase III study into one single confirmatory clinical trial. Several examples of such designs are presented, where the primary endpoint is binary, time-to-event or continuous. The interim adaptations considered include the selection of treatments and the selection of hypotheses related to a pre-specified subgroup of patients. Practical aspects concerning the planning and implementation of adaptive seamless confirmatory studies are also discussed.

Entities:  

Mesh:

Year:  2006        PMID: 16972715     DOI: 10.1002/bimj.200510231

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  14 in total

1.  Interim analyses in diagnostic versus treatment studies: differences and similarities.

Authors:  Oke Gerke; Poul Flemming Høilund-Carlsen; Mads Hvid Poulsen; Werner Vach
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

2.  Seamless Phase IIa/IIb and enhanced dose-finding adaptive design.

Authors:  Jiacheng Yuan; Herbert Pang; Tiejun Tong; Dong Xi; Wenzhao Guo; Peter Mesenbrink
Journal:  J Biopharm Stat       Date:  2015-09-21       Impact factor: 1.051

3.  Adaptive design of confirmatory trials: Advances and challenges.

Authors:  Tze Leung Lai; Philip W Lavori; Ka Wai Tsang
Journal:  Contemp Clin Trials       Date:  2015-06-14       Impact factor: 2.226

4.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

5.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

Review 6.  Integrated phase II/III clinical trials in oncology: a case study.

Authors:  Meihua Wang; James J Dignam; Qiang E Zhang; John F DeGroot; Minesh P Mehta; Sally Hunsberger
Journal:  Clin Trials       Date:  2012-11-22       Impact factor: 2.486

7.  Optimizing the data combination rule for seamless phase II/III clinical trials.

Authors:  Lisa V Hampson; Christopher Jennison
Journal:  Stat Med       Date:  2014-10-15       Impact factor: 2.373

8.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

Authors:  Matthew R Sydes; Mahesh K B Parmar; Nicholas D James; Noel W Clarke; David P Dearnaley; Malcolm D Mason; Rachel C Morgan; Karen Sanders; Patrick Royston
Journal:  Trials       Date:  2009-06-11       Impact factor: 2.279

9.  A multi-stage drop-the-losers design for multi-arm clinical trials.

Authors:  James Wason; Nigel Stallard; Jack Bowden; Christopher Jennison
Journal:  Stat Methods Med Res       Date:  2016-09-30       Impact factor: 3.021

10.  Speeding up the evaluation of new agents in cancer.

Authors:  Mahesh K B Parmar; Friederike M-S Barthel; Matthew Sydes; Ruth Langley; Rick Kaplan; Elizabeth Eisenhauer; Mark Brady; Nicholas James; Michael A Bookman; Ann-Marie Swart; Wendi Qian; Patrick Royston
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.